281 related articles for article (PubMed ID: 8638000)
1. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
4. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
6. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
7. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
9. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
10. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
11. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
12. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
13. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
14. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.
Griffeth LK; Dehdashti F; McGuire AH; McGuire DJ; Perry DJ; Moerlein SM; Siegel BA
Radiology; 1992 Jan; 182(1):185-94. PubMed ID: 1727280
[TBL] [Abstract][Full Text] [Related]
15. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
16. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
18. 11C-acetate PET imaging of prostate cancer.
Oyama N; Akino H; Kanamaru H; Suzuki Y; Muramoto S; Yonekura Y; Sadato N; Yamamoto K; Okada K
J Nucl Med; 2002 Feb; 43(2):181-6. PubMed ID: 11850482
[TBL] [Abstract][Full Text] [Related]
19. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
Bury T; Barreto A; Daenen F; Barthelemy N; Ghaye B; Rigo P
Eur J Nucl Med; 1998 Sep; 25(9):1244-7. PubMed ID: 9724372
[TBL] [Abstract][Full Text] [Related]
20. The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
Takahashi N; Inoue T; Lee J; Yamaguchi T; Shizukuishi K
Oncology; 2007; 72(3-4):226-33. PubMed ID: 18176088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]